Home / Health / New Drug Halts Paralysis, Offers Hope for Nerve Disease
New Drug Halts Paralysis, Offers Hope for Nerve Disease
19 Aug
Summary
- Experimental drug tanruprubart targets Guillain-Barré syndrome.
- The drug showed rapid muscle strength gains in early trials.
- Annexon plans FDA submission in late 2026.
An experimental drug called tanruprubart is advancing as a potential first-ever targeted immunotherapy for Guillain-Barré syndrome (GBS). This condition causes the immune system to attack nerves, leading to paralysis. Recent clinical results, though not yet peer-reviewed, demonstrate that a single infusion of tanruprubart can significantly halt nerve damage and expedite patient recovery.
The drug works by blocking C1q, a molecule that initiates the immune assault on nerve cells. Data from a real-world study indicated patients receiving tanruprubart experienced substantial muscle strength improvements within the first week compared to standard treatments. These benefits, including enhanced mobility and independence, were sustained up to 26 weeks.
Annexon Biosciences plans to submit a Biologics License Application to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026. This submission will be based on ongoing studies conducted in the U.S. and Europe. If approved, tanruprubart would represent a significant therapeutic advancement for GBS patients globally.
